Alebund soars in Hong Kong debut on kidney treatment hopes
The drug developer stood out from the IPO crowd of unprofitable biotechs due to its existing revenue stream and a focus on novel remedies for renal disease Key Takeaways: Alebund…
BRIEF: Everest Medicines advances with major licensing deal, new drug application approval
Everest Medicines Ltd. (1952.HK) last Thursday announced an exclusive licensing agreement to commercialize Micot’s MT1013 for the treatment of secondary hyperparathyroidism (SHPT), worth up to 1.24 billion yuan ($179 million).…
Everest Medicines drives growth with AI-powered mRNA pipeline
The company said the U.S. FDA has cleared the IND application for its self-developed EVM14, a tumor-associated antigen vaccine Key Takeaways: The FDA has cleared Everest Medicine’s EVM14 cancer vaccine…
BRIEF: Everest unveils positive results for kidney drug EVER001 in Phase 1b/2a trial
Everest Medicines (1952.HK) announced on Wednesday that its EVER001, a next-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor for treatment of primary membranous nephropathy (pMN), showed positive results in its…
A McDonald’s Valuation Downsize, and New Medical Plan Additions
The value of McDonald's China operation has plunged by more than half in the last year. And 91 companies got their drugs added to China's national health plan By Doug…
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
Nefecon’s addition to China’s NRDL will increase its reach and market share, lifting the drug’s competitive advantage and brand recognition Key Takeaways: Everest Medicines’ Nefecon kidney drug was approved for…
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
The innovative drug maker’s stock jumped more than 18% in a single day on high hopes for inclusion of its blockbuster new drug, Nefecon, in China’s national reimbursement drug list…
Recent Articles
RELATED ARTICLES
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK - Jacobio Pharma poised to turn a profit from precision cancer drugs
- Investors pile onto TenNor IPO with hopes for new type of gastric drug
- NEWS WRAP: Ribo Life enters Hong Kong biotech fast lane after strong debut
- A healthy return: drug spin-off nets Keymed up to $320 million
-
Huaqin stock rises in Hong Kong debut as AI data center business booms
3296.HK603296.SHG
